Innogen  ·  Publications  ·  Briefings
Appropriate Governance of the Life Sciences (01)
Multinational Company Innovation Strategies

This paper examines this remarkable robustness in the pharmaceutical innovation model, but also recognises that disruptive change is becoming increasingly inevitable.

It focuses on the combinations of circumstances likely to lead to radical disruption and points to the need for such change to be carefully managed to ensure that life science research continues to deliver both public and commercial benefits.